Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
Natalizumab (Tysabri) is a monoclonal antibody (α4 integrin antagonist) approved for treatment of multiple sclerosis, both for patients who fail therapy with other disease modifying agents and for patients with aggressive disease. Natalizumab is highly effective, resulting in significant decreases i...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2015-01-01
|
| Series: | Multiple Sclerosis International |
| Online Access: | http://dx.doi.org/10.1155/2015/809252 |